Proteome out-licenses stroke biomarkers
UK-based Proteome Sciences has licenced its biomarkers for the detection, diagnosis and monitoring of stroke to an undisclosed firm, which it says is one of the top 10 global leaders in clinical diagnostics.
Proteome stated that this is a new area for the licencee, which has determined not to disclose its identity for competitive reasons. The biomarkers were discovered and validated using a combination of different proteomic approaches available for external use through the proprietary ProteoSHOP platform.
Under the terms of the deal, a number of Proteome Sciences' biomarkers will be tested in stroke for inclusion on a new panel for the licencee's high-throughput diagnostic platforms. Financial details were disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze